X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs WOCKHARDT LTD. - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH WOCKHARDT LTD. PANACEA BIOTECH/
WOCKHARDT LTD.
 
P/E (TTM) x 178.7 -15.7 - View Chart
P/BV x 4.0 2.6 154.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 PANACEA BIOTECH   WOCKHARDT LTD.
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
WOCKHARDT LTD.
Mar-17
PANACEA BIOTECH/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1491,129 13.2%   
Low Rs82627 13.1%   
Sales per share (Unadj.) Rs84.1363.1 23.2%  
Earnings per share (Unadj.) Rs-18.3-20.4 89.5%  
Cash flow per share (Unadj.) Rs-6.7-7.0 96.0%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs83.7301.8 27.7%  
Shares outstanding (eoy) m61.25110.55 55.4%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x1.42.4 56.8%   
Avg P/E ratio x-6.3-42.9 14.7%  
P/CF ratio (eoy) x-17.2-125.9 13.7%  
Price / Book Value ratio x1.42.9 47.4%  
Dividend payout %0-48.9 0.0%   
Avg Mkt Cap Rs m7,07497,063 7.3%   
No. of employees `0002.86.8 40.6%   
Total wages/salary Rs m1,4499,665 15.0%   
Avg. sales/employee Rs Th1,874.15,931.8 31.6%   
Avg. wages/employee Rs Th527.01,428.1 36.9%   
Avg. net profit/employee Rs Th-407.7-334.0 122.1%   
INCOME DATA
Net Sales Rs m5,15440,146 12.8%  
Other income Rs m1001,143 8.7%   
Total revenues Rs m5,25441,289 12.7%   
Gross profit Rs m-766128 -598.7%  
Depreciation Rs m7111,489 47.7%   
Interest Rs m1,5032,253 66.7%   
Profit before tax Rs m-2,881-2,472 116.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17-211 -8.0%   
Profit after tax Rs m-1,121-2,260 49.6%  
Gross profit margin %-14.90.3 -4,663.5%  
Effective tax rate %-0.68.5 -6.8%   
Net profit margin %-21.8-5.6 386.4%  
BALANCE SHEET DATA
Current assets Rs m3,81046,160 8.3%   
Current liabilities Rs m8,36519,258 43.4%   
Net working cap to sales %-88.467.0 -131.9%  
Current ratio x0.52.4 19.0%  
Inventory Days Days156101 154.5%  
Debtors Days Days6794 71.5%  
Net fixed assets Rs m14,48040,165 36.1%   
Share capital Rs m61553 11.1%   
"Free" reserves Rs m90332,814 2.8%   
Net worth Rs m5,12733,367 15.4%   
Long term debt Rs m5,83231,903 18.3%   
Total assets Rs m19,43389,687 21.7%  
Interest coverage x-0.9-0.1 943.6%   
Debt to equity ratio x1.11.0 119.0%  
Sales to assets ratio x0.30.4 59.2%   
Return on assets %2.00 -22,877.7%  
Return on equity %-21.9-6.8 322.8%  
Return on capital %3.6-0.3 -1,084.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,5399,121 16.9%   
Fx outflow Rs m9422,133 44.2%   
Net fx Rs m5976,988 8.5%   
CASH FLOW
From Operations Rs m599-2,695 -22.2%  
From Investments Rs m-438-6,863 6.4%  
From Financial Activity Rs m-30312,545 -2.4%  
Net Cashflow Rs m-1413,010 -4.7%  

Share Holding

Indian Promoters % 74.5 74.5 100.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 2.3 26.1%  
FIIs % 1.3 7.7 16.9%  
ADR/GDR % 0.0 0.1 -  
Free float % 23.6 15.4 153.2%  
Shareholders   10,259 67,757 15.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  ALEMBIC LTD  DR. REDDYS LAB  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 23, 2018 02:23 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - NATCO PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS